Revolution Medicines (RVMD) updated its FY26 GAAP operating expenses guidance to a range of $1.7B-$1.8B. The expected increase in operating expenses is due to higher projected non-cash stock-based compensation expense for FY26, now estimated to be between $260M-$280M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- FDA permits expanded access for Revolution pancreatic cancer drug
- Erasca price target raised to $9 from $2 at BofA
- Erasca believes Revolution infringement claims ‘without merit,’ says Stifel
- Erasca sinks after Revolution Medicines alleges patent infringement
- Revolution Medicines: Daraxonrasib Data De‑Risk Pivotal Pancreatic Cancer Program, Supporting Buy Rating and $169 Target